查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867091

電腦輔助藥物發現市場：按分子類型、實施模式、定價模式、最終用戶、類型、技術和應用分類——2025-2032年全球預測

Computer-aided Drug Discovery Market by Molecule Type, Deployment Model, Pricing Model, End User, Type, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，電腦輔助藥物發現市場將成長至 88 億美元，複合年成長率為 10.05%。

關鍵市場統計數據
基準年 2024 40.8億美元
預計年份：2025年 44.9億美元
預測年份 2032 88億美元
複合年成長率 (%) 10.05%

整合式人工智慧驅動工作流程、雲端規模資料平台和多學科夥伴關係如何加速候選藥物識別並變革藥物發現中的轉換決策

先進計算技術、大型生物資料集和演算法創新的融合正引領藥物發現進入一個新時代。計算方法不再局限於孤立的任務，而是成為貫穿整個流程的關鍵驅動力，影響目標選擇、先導化合物發現、先導藥物最適化和臨床前安全性評估。因此，各機構正在重新思考如何設計藥物發現工作流程、組織團隊以及建立外部夥伴關係，以充分利用更快的假設生成和更具預測性的In Silico評估。

本報告整合了電腦輔助藥物發現領域的當代實踐和新興能力，重點闡述了調查方法、投資選擇和企業行為如何共同影響轉換成果。報告著重介紹了基於實證的發展，例如分子模擬技術的日益精進、生物化學方法的日益成熟以及雲端運算在支持迭代實驗方面發揮的日益重要的作用。透過將技術能力與組織因素聯繫起來，本報告旨在為研究領導者和高階主管提供一個清晰的框架，以幫助他們確定投資和合作的優先順序。透過對技術趨勢、商業性活動和監管介面的深入分析，本報告指出了潛在的競爭優勢領域以及獲取這些優勢所需的營運變革。

基於物理的建模、衍生設計以及分子模擬精度的不斷提高，正在重新定義早期藥物發現的限制，並推動探索新的治療模式。

電腦輔助藥物發現領域正經歷著變革性的轉變，這既得益於技術能力的提升，也得益於產業實踐的演進。機器學習架構和物理資訊建模的進步提高了In Silico預測的可解釋性和可靠性，使研究團隊能夠更有信心地確定實驗的優先順序。同時，互通資料標準和聯邦學習方法的普及，在保護資料隱私和來源資訊的同時，也降低了多機構合作的阻力。

在組織層面，藥物研發正從孤立的演算法實驗轉向涵蓋生物學、化學和安全性的整合式藥物發現平台，這項轉變已十分明顯。這種轉變催生了新型態的夥伴關係模式：既包括將供應商工具整合到內部工作流程中的長期平台聯盟，也包括旨在加速特定專案的短期專家合作。資金籌措模式和內部管治也不斷調整，各機構紛紛建立專家中心，以管理模型管治、可重複性以及資料的倫理使用。這些變化共同縮短了決策時間，並提高了將計算假設轉化為可執行實驗方案的可能性。

重要的是，技術的日趨成熟正在拓展藥物研發的領域，生物製藥和小分子藥物均受益於改良的設計工具。因此，各機構擴大組成混合型團隊，將傳統藥物化學專家與計算科學家結合，以產生和檢驗複雜的假設。這種技能、工具和流程的全面調整，標誌著藥物研發專案構思和執行方式的根本性轉變。

檢驗美國關稅政策在2025年的累積影響：供應鏈動態、計算工具採購、醫藥研發領域的國際合作

2025年，美國推出的貿易政策措施對計算藥物發現生態系統的採購、部署和全球合作模式產生了顯著影響。關稅及相關貿易措施加強了對專用硬體和軟體供應鏈的審查，促使各機構重新評估供應商關係，並考慮關鍵運算資源的在地化策略。這種重新評估正在影響總體擁有成本、計劃進度以及跨境研究舉措的靈活性。

因此，一些組織優先考慮策略性地儲備運算能力，並尋求多源合約以降低中斷風險。另一些組織則加快向擁有分散式基礎設施的雲端服務供應商遷移，以在關稅帶來的不確定性下維持對GPU和TPU資源的存取。同時，國際合作也透過審查合約條款、重新定義硬體交付責任以及採用標準化容器化來調整策略，從而促進跨司法管轄區的可複現性。

在創新方面，關稅相關的壓力促使各團隊更加關注軟體的可移植性和開放標準的採用，這主要是由於他們努力避免被供應商鎖定，而地緣政治貿易緊張局勢可能會加劇這種情況。監管合規和出口管制在採購決策中也變得越來越重要，導致法律和合規部門積極參與技術評估。這些累積效應正在重塑整個發現生態系統的籌資策略和合作模式，並將韌性作為技術選擇的核心標準。

從細分市場的角度深入了解分子類型、部署模式、定價結構、最終用戶、解決方案類型、底層技術以及應用主導的採用模式

精細化的細分框架揭示了產品和服務的不同維度如何影響能力部署和價值創造。基於分子類型進行區分，生物製劑和小分子化合物的計算需求各不相同：生物製劑的工作流程側重於序列分析、結構建模和免疫抗原性預測，而小分子項目則優先考慮配體-蛋白質相互作用、理化性質最佳化和合成可行性評估。這些不同的需求導致了不同的技術組合和團隊結構。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 生成式深度學習架構在新型小分子設計與最佳化的應用
  • 將多組體學數據與人工智慧驅動模型結合，以實現精準的藥物標靶識別和檢驗。
  • 透過部署雲端原生高效能運算平台加速虛擬篩檢工作流程
  • 量子計算演算法提高了分子對接和結合親和性預測的準確性。
  • 透過實施可解釋人工智慧技術，實現透明的候選藥物篩選和優先排序。
  • 利用整合人工智慧的自主機器人實驗室進行高通量合成和即時檢測最佳化
  • 開發用於預測早期藥物研發中藥物動力學和毒性的數位雙胞胎模型

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按分子類型分類的電腦輔助藥物發現市場

  • 生物製劑
  • 低分子化合物

9. 按部署模式分類的電腦輔助藥物發現市場

  • 雲端基礎的
  • 本地部署

第10章：電腦輔助藥物發現市場定價模式

  • 付費使用制
  • 永久許可
  • 訂閱

第11章：電腦輔助藥物發現市場（按最終用戶分類）

  • 學術和政府機構
  • 生技公司
  • CRO（合約研究組織）
  • 製藥公司

第12章：電腦輔助藥物發現市場（按類型分類）

  • 服務
    • 諮詢
    • 介紹
    • 研究委員會
    • 支援與維護
  • 軟體
    • 數據分析
    • 全新設計
    • 分子建模
      • 基於配體的設計
      • 基於結構的設計
    • QSAR建模
    • 虛擬篩檢

第13章：按技術分類的電腦輔助藥物發現市場

  • ADMET預測
  • 生物資訊學
    • 功能基因體學
    • 序列分析
  • 化學資訊學
    • 圖書館設計
    • QSAR建模
    • 鷹架跳躍
  • 全新設計
  • 分子建模

第14章：電腦輔助藥物發現市場（按應用領域分類）

  • 臨床試驗支持
  • 潛在客戶開發
  • 先導藥物最適化
  • 臨床前開發
  • 目標識別

第15章：按地區分類的電腦輔助藥物發現市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：按組別分類的電腦輔助藥物發現市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：各國電腦輔助藥物發現市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Schrodinger, Inc.
    • Dassault Systemes SE
    • Certara, LP
    • Exscientia Limited
    • Atomwise, Inc.
    • Cresset, Ltd.
    • OpenEye Scientific Software, Inc.
    • Nimbus Therapeutics, LLC
    • Insilico Medicine, Inc.
    • BenevolentAI Limited
Product Code: MRR-5D693B46C018

The Computer-aided Drug Discovery Market is projected to grow by USD 8.80 billion at a CAGR of 10.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.08 billion
Estimated Year [2025] USD 4.49 billion
Forecast Year [2032] USD 8.80 billion
CAGR (%) 10.05%

How integrated AI-driven workflows, cloud-scale data platforms, and cross-disciplinary partnerships are accelerating candidate identification and transforming translational decision-making in drug discovery

The convergence of advanced computation, large-scale biological datasets, and algorithmic innovation is ushering in a new era for drug discovery. Computational methods are no longer confined to isolated tasks; they have become integral, end-to-end enablers that influence target selection, hit identification, lead optimization, and preclinical safety evaluation. As a result, organizations are rethinking how discovery workflows are designed, how teams are arranged, and how external partnerships are structured to take advantage of faster hypothesis generation and more predictive in silico evaluations.

This report synthesizes contemporary practice and emergent capabilities in computer-aided drug discovery, focusing on how methodologies, deployment choices, and enterprise behaviors collectively shape translational outcomes. The narrative emphasizes evidence-based developments such as greater fidelity in molecular simulations, the maturation of generative chemistry approaches, and the expanding role of cloud-scale compute in enabling iterative experimentation. By connecting technological capabilities to organizational implications, the intent is to equip research leaders and business executives with a clear framework for prioritizing investments and collaborations. Through careful analysis of technology trends, commercial behaviors, and regulatory touchpoints, the report frames where competitive advantage is likely to arise and what operational changes will be required to capture it.

Strategic emergence of physics-based modeling, generative design, and expanded molecular simulation fidelity that are redefining early discovery constraints and enabling novel modality exploration

The landscape of computational drug discovery is undergoing transformative shifts driven by both capability enhancements and evolving industry practices. Advances in machine learning architectures and physics-informed modeling have improved the interpretability and reliability of in silico predictions, enabling teams to prioritize experiments with greater confidence. Concurrently, the proliferation of interoperable data standards and federated learning approaches is reducing the friction of multi-institutional collaboration while preserving data privacy and provenance.

Organizationally, there is a clear pivot from siloed algorithmic experiments toward integrated discovery platforms that span biology, chemistry, and safety. This shift has prompted new partnership archetypes: long-term platform partnerships that embed vendor tools into internal workflows, and short-term specialist engagements that accelerate specific programs. Funding patterns and internal governance have also adapted, with entities establishing centres of excellence to manage model governance, reproducibility, and ethical use of data. These shifts collectively reduce time-to-decision and increase the likelihood that computational hypotheses translate into viable experimental programs.

Importantly, the technology maturation has broadened modality exploration; biologics and small molecules alike benefit from improved design tools. As a result, organizations are increasingly blending traditional medicinal chemistry expertise with computational scientists, creating hybrid teams that can both generate and validate complex hypotheses. This holistic realignment of skills, tools, and processes marks a fundamental change in how discovery programs are conceived and executed.

Examining cumulative effects of United States tariff policies in 2025 on supply chains, computational tool sourcing, and international collaboration dynamics within drug discovery

In 2025, trade policy actions introduced by the United States have had measurable implications for the procurement, deployment, and global collaboration patterns within computational drug discovery ecosystems. Tariffs and related trade measures have increased scrutiny over supply chains for specialized hardware and software, prompting organizations to reassess vendor relationships and consider localization strategies for critical computational assets. This reassessment has implications for total cost of ownership, project timelines, and the agility of cross-border research initiatives.

As a consequence, some organizations prioritized strategic stockpiling of compute capacity and sought multi-sourcing agreements to mitigate disruption risk. Others accelerated migration to cloud providers with distributed footprints to preserve access to GPU and TPU resources despite tariff-driven uncertainty. In parallel, international collaborations adapted by shifting contractual terms, redefining responsibilities for hardware provision, and embracing standardized containerization to ease replication across jurisdictions.

On the innovation front, tariff-related pressures encouraged tighter attention to software portability and open standard adoption, as teams aimed to avoid vendor lock-in that could be exacerbated by geopolitical trade frictions. Regulatory compliance and export controls also gained prominence in procurement decisions, with legal and compliance functions becoming active participants in technology evaluation. These cumulative effects have reshaped procurement strategies and collaborative models across the discovery ecosystem, reinforcing resilience as a central criterion for technology selection.

Segment-level intelligence into molecule types, deployment models, pricing structures, end users, solution types, enabling technologies, and application-driven adoption patterns

A nuanced segmentation framework reveals how different dimensions of offering and adoption influence capability deployment and value capture. Based on molecule type, differentiation emerges between biologics and small molecules with distinct computational requirements: biologics workflows emphasize sequence analysis, structural modeling, and immunogenicity prediction, whereas small molecule programs prioritize ligand-protein interactions, physicochemical property optimization, and synthetic accessibility assessments. These divergent needs drive varied technology mixes and team structures.

Based on deployment model, choices between cloud-based and on-premises delivery shape scalability and data governance trade-offs. Cloud-based approaches facilitate burst compute and collaborative federated learning, while on-premises deployments remain attractive for organizations with strict data residency or security constraints. Based on pricing model, organizations select between pay-per-use, perpetual license, and subscription arrangements to align financial exposure with project tempo and budget predictability.

Based on end user, adoption patterns differ across academic and government institutes, biotechnology companies, contract research organizations, and pharmaceutical companies, each prioritizing different combinations of flexibility, depth of customization, and regulatory alignment. Based on type, offerings split into services and software. Services encompass consulting, implementation, research outsourcing, and support and maintenance, providing hands-on expertise and operational integration. Software splits into data analytics, de novo design, molecular modeling, QSAR modeling, and virtual screening, with molecular modeling further divided into ligand-based design and structure-based design, reflecting the need for both top-down and bottom-up computational strategies.

Based on technology, capabilities include ADMET prediction, bioinformatics, chemoinformatics, de novo design, and molecular modeling. Within bioinformatics there is emphasis on functional genomics and sequence analysis, while chemoinformatics covers library design, QSAR modeling, and scaffold hopping. Based on application, use cases such as clinical trials support, lead discovery, lead optimization, preclinical development, and target identification illustrate how technology stacks are mapped to specific translational objectives. These segmentation lenses together inform where investments will yield the highest strategic return and how vendors can tailor their value propositions to distinct customer archetypes.

Regional intelligence highlighting Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influencing talent flows, regulatory alignment, and infrastructure investment priorities

Regional dynamics critically influence the evolution of computational drug discovery capabilities, with each geography presenting distinct strengths and constraints that shape strategic planning. In the Americas, concentration of biopharma research centers, access to venture capital, and a dense ecosystem of technology vendors promote rapid adoption of advanced computational platforms. This environment supports accelerated commercialization pathways and close ties between discovery teams and translational development partners.

In Europe, Middle East & Africa, regulatory harmonization efforts and strong academic-industrial collaborations foster rigorous validation practices and a focus on reproducibility. Investment patterns in this region often emphasize public-private partnerships and infrastructure that supports precompetitive data sharing. These features contribute to robust methodological standards and collaborative networks that underpin long-term capability building.

In Asia-Pacific, rapid expansion of research infrastructure, significant public sector investment in biotechnology, and a growing pool of computational talent create an environment conducive to large-scale data initiatives and high-throughput screening programs. This region increasingly becomes a hub for both contract research activity and end-to-end discovery programs, leveraging cost efficiencies and scaling advantages. Across regions, differences in regulatory regimes, talent availability, and infrastructure maturity inform where organizations choose to centralize or decentralize capabilities, and those choices in turn shape partnership strategies and operational models.

Competitive and collaborative company insights focusing on platform differentiation, service portfolios, partnerships, and intellectual property strategies shaping the industry landscape

Company behavior in the computational discovery space is characterized by a mix of product differentiation, platform bundling, and strategic partnerships. Leading firms emphasize integrated platforms that combine data management, modeling engines, and visualization tools to lower the barrier for multidisciplinary teams to adopt computational approaches. Others focus on niche capabilities-such as generative chemistry, high-fidelity molecular dynamics, or specialized ADMET prediction modules-to serve domain-specific needs and develop defensible expertise.

Partnerships between software vendors and contract research organizations or laboratory automation providers are increasingly common, enabling end-to-end workflows that connect in silico hypothesis generation with rapid experimental validation. Intellectual property strategies often center on proprietary model architectures and curated datasets that provide predictive advantage, while open-source contributions and community benchmarks play a role in driving adoption and improving model transparency.

Service providers differentiate through consulting capabilities that translate algorithmic outputs into experimental plans, and through implementation teams that embed tools into existing discovery pipelines. Across the competitive landscape, companies that demonstrate interoperability, strong evidence of predictive performance, and a commitment to rigorous validation tend to secure longer-term engagements. Strategic alliances with academic institutions, clinical networks, and data custodians further expand access to curated datasets that enhance model training and validation, reinforcing a virtuous cycle of capability improvement for those organizations able to navigate complex partnership ecosystems.

Actionable recommendations for industry leaders to prioritize capability investments, partnership models, governance frameworks, and talent strategies for sustainable competitive advantage

Industry leaders should adopt a pragmatic, phased approach to integrating computational discovery into core R&D. First, prioritize capability investments that address immediate translational bottlenecks, such as improving prediction of ADMET properties or strengthening target validation pipelines. Align these investments with a governance framework that mandates reproducibility, model documentation, and routine back-testing against experimental outcomes to ensure sustained confidence in computational outputs.

Second, cultivate hybrid talent models that embed computational scientists alongside medicinal chemists and biologists to ensure hypotheses are both computationally sound and experimentally tractable. Invest in internal training programs and cross-functional rotations to accelerate knowledge transfer and reduce dependency on external consultants. Third, pursue partnership models that balance strategic platform commitments with the flexibility of specialist engagements, thereby preserving the ability to pilot new approaches while securing long-term integration where it delivers clear operational benefits.

Fourth, adopt procurement and architecture choices that mitigate geopolitical and supply chain risks, including multi-cloud strategies, software portability, and contractual clauses for continuity of service. Fifth, implement metrics and dashboards that translate computational performance into experimental productivity measures, thereby enabling continuous improvement and clearer ROI conversations with stakeholders. Together, these recommendations form an actionable roadmap for organizations aiming to derive consistent, reproducible value from computational drug discovery investments.

Transparent multidisciplinary research methodology describing data sources, expert validation, modeling approaches, and steps taken to ensure reproducibility and analytical rigor

This study employs a multidisciplinary research methodology combining primary expert interviews, secondary literature synthesis, and technical evaluation of representative tools and workflows. Primary inputs include structured conversations with discovery scientists, platform engineers, and procurement specialists, which informed judgment on adoption barriers, governance practices, and organizational readiness. Secondary sources encompassed peer-reviewed literature, preprints, and industry white papers to triangulate technological capabilities and evidence of predictive performance.

Technical evaluations involved reproducibility checks on benchmark datasets, assessment of model explainability features, and review of integration capabilities with laboratory information management systems and automation platforms. Wherever possible, findings were validated with case examples that illustrate how specific computational approaches impacted experimental throughput or decision-making processes. Ethical considerations and data governance practices were explicitly examined to ensure recommendations are implementable within prevailing regulatory regimes.

Analytical rigor was maintained through documented methodologies for data collection, transparent criteria for inclusion of tools and vendors in the study, and cross-validation of qualitative inputs. Limitations and assumptions are clearly articulated to support appropriate interpretation of conclusions and to enable organizations to adapt the approach to their unique contexts. This structured methodology ensures that the report's insights are both evidence-based and operationally relevant.

Concluding synthesis summarizing strategic takeaways, risk factors, and forward-looking considerations for organizations navigating a rapidly evolving computational drug discovery ecosystem

In summary, computational drug discovery has transitioned from a set of supporting tools to a strategic pillar that reshapes how hypotheses are generated, prioritized, and validated. Technological advances in machine learning, molecular simulation, and data engineering have enhanced predictive fidelity and reduced translational risk when paired with robust experimental validation. Organizations that align governance, talent, and procurement strategies with these capabilities are positioned to accelerate discovery cycles and increase the efficiency of resource allocation.

Key risk factors include geopolitical and trade-related perturbations to hardware and software supply chains, the potential for model overfitting without rigorous validation, and the need for clear governance around data provenance and ethical use. Nevertheless, institutions that invest in interoperable architectures, hybrid talent models, and strategic partnerships can convert these challenges into sources of resilience and competitive differentiation. The path forward requires disciplined experimentation, transparent measurement of computational performance against experimental outcomes, and a willingness to adapt organizational structures to sustain cross-disciplinary collaboration.

Ultimately, success in this evolving ecosystem will be defined by the ability to integrate computational insights seamlessly into laboratory decision-making, maintain reproducibility and model governance, and scale capabilities in a way that aligns with translational imperatives and regulatory expectations. This synthesis provides a foundation for executives to make informed decisions about where to focus resources and how to structure partnerships for long-term impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Application of generative deep learning frameworks for de novo small molecule design and optimization
  • 5.2. Integration of multi-omics data and AI-driven models for precision drug target identification and validation
  • 5.3. Deployment of cloud-native high-performance computing platforms for accelerated virtual screening workflows
  • 5.4. Adoption of quantum computing algorithms to enhance accuracy of molecular docking and binding affinity predictions
  • 5.5. Implementation of explainable artificial intelligence techniques for transparent drug candidate selection and prioritization
  • 5.6. Utilization of autonomous robotic labs integrated with AI for high-throughput synthesis and real-time assay optimization
  • 5.7. Development of digital twin models for in silico pharmacokinetics and toxicity prediction in early drug discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Computer-aided Drug Discovery Market, by Molecule Type

  • 8.1. Biologics
  • 8.2. Small Molecules

9. Computer-aided Drug Discovery Market, by Deployment Model

  • 9.1. Cloud-Based
  • 9.2. On-Premises

10. Computer-aided Drug Discovery Market, by Pricing Model

  • 10.1. Pay Per Use
  • 10.2. Perpetual License
  • 10.3. Subscription

11. Computer-aided Drug Discovery Market, by End User

  • 11.1. Academic And Government Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. Computer-aided Drug Discovery Market, by Type

  • 12.1. Services
    • 12.1.1. Consulting
    • 12.1.2. Implementation
    • 12.1.3. Research Outsourcing
    • 12.1.4. Support And Maintenance
  • 12.2. Software
    • 12.2.1. Data Analytics
    • 12.2.2. De Novo Design
    • 12.2.3. Molecular Modeling
      • 12.2.3.1. Ligand Based Design
      • 12.2.3.2. Structure Based Design
    • 12.2.4. QSAR Modeling
    • 12.2.5. Virtual Screening

13. Computer-aided Drug Discovery Market, by Technology

  • 13.1. ADMET Prediction
  • 13.2. Bioinformatics
    • 13.2.1. Functional Genomics
    • 13.2.2. Sequence Analysis
  • 13.3. Chemoinformatics
    • 13.3.1. Library Design
    • 13.3.2. QSAR Modeling
    • 13.3.3. Scaffold Hopping
  • 13.4. De Novo Design
  • 13.5. Molecular Modeling

14. Computer-aided Drug Discovery Market, by Application

  • 14.1. Clinical Trials Support
  • 14.2. Lead Discovery
  • 14.3. Lead Optimization
  • 14.4. Preclinical Development
  • 14.5. Target Identification

15. Computer-aided Drug Discovery Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Computer-aided Drug Discovery Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Computer-aided Drug Discovery Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Schrodinger, Inc.
    • 18.3.2. Dassault Systemes SE
    • 18.3.3. Certara, L.P.
    • 18.3.4. Exscientia Limited
    • 18.3.5. Atomwise, Inc.
    • 18.3.6. Cresset, Ltd.
    • 18.3.7. OpenEye Scientific Software, Inc.
    • 18.3.8. Nimbus Therapeutics, LLC
    • 18.3.9. Insilico Medicine, Inc.
    • 18.3.10. BenevolentAI Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICA